

# PROGRAM | THURSDAY 16 JUNE

08:30 - 09:00 Registration & coffee

09:00 - 09:15 Welcome by Max Mazzone

## Session 1

### CROSS TALK MYELOID CELLS

Chair: Max Mazzone

09:15 - 09:45 A tumor agnostic dendritic cell vaccine  
**Michele De Palma**, *Swiss Federal Institute of Technology in Lausanne (EPFL) and Agora Cancer Research Center, Lausanne, CH*

09:45 - 10:15 Necrophagia, DaNGeRous indigestion and immunity to cancer  
**Caetano Reis e Sousa**, *The Francis Crick Institute, UK*

10:15 - 10:45 Coffee break

10:45 - 11:15 Generation and functions of pro-metastatic neutrophils  
**Mikala Egeblad**, *Cold Spring Harbor Laboratory, US*

11:15 - 11:20 *Poster pitch:* Lymphatic endothelial cell autophagy control of S1P shapes lymphocyte trafficking in the lymph node and T cell mediated anti-tumor immune responses (Poster #39)  
**Diede Houbaert**, *VIB-KU Leuven Center for Cancer Biology, BE*

11:20 - 11:25 *Poster pitch:* Radiotherapy modulates macrophage-cancer cell crosstalk: an opportunity towards the development of novel Immunomodulatory therapies (Poster #15)  
**Maria José Oliveira**, *i3S – Institute of Investigation and Innovation in Health, University of Porto, PT*

11:25 - 11:30 *Poster pitch:* Mucosal vaccination with a viral vector vaccine induces robust lung-resident T cell responses and protects against 4T1 metastasis (Poster #61)  
**Friederike Oltmanns**, *Clinical and Molecular Virology, Erlangen, DE*

11:30 - 11:35 *Poster pitch:* IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer (Poster #76)

**Lorenzo Spagnuolo**, *The Netherlands Cancer Institute, NL; Oncode Institute, NL*

11:35 - 11:40 *Poster pitch:* Deep T cell receptor sequencing reveals common and reproducible T cell receptor signatures of response to checkpoint immunotherapy (Poster #86)

**Robert Watson**, *Oxford University Hospitals NHS Foundation Trust, UK; University of Oxford, UK*

11:45 - 11:50 *Company pitch:* Explore the next step in ultrahigh-content imaging: the MACSima imaging platform

**Veerle Lemmens**, *Imaging Specialist BeNeLux Miltenyi Biotec, BE*

11:50 - 12:45 Lunch

12:45 - 13:45 Poster Session 1 | numbers 1 - 44

## Session 2

### IMMUNOMETABOLISM

Chair: Patrizia Agostinis

- 13:45 - 14:15** Immunoediting instructs tumor metabolic reprogramming to support immune evasion  
**Ping-Chih Ho**, *University of Lausanne/Ludwig Institute for Cancer Research, CH*
- 14:15 - 14:45** Co-opting immune cells to support cancer progression through metabolic reprogramming  
**Susan Kaech**, *NOMIS Center for Immunobiology & Microbial Pathogenesis, Salk Institute for Biological Studies, US*
- 14:45 - 15:15** Functional genomics of T cell metabolism and immuno-oncology  
**Hongbo Chi**, *St. Jude Children's Research Hospital, US*
- 15:15 - 15:30** *Selected talk:* Harnessing CD8+ T cell metabolism to improve their anti-tumor immune response in pancreatic cancer  
**Samantha Pretto**, *VIB-KU Leuven Center for Cancer Biology, BE*
- 15:30 - 16:00** Coffee break

## Session 3

### CLINICAL OR TRANSLATIONAL

Chair: Alexandre Harari

- 16:00 - 16:30** Personalized whole tumor lysate vaccines in the new era of neo-antigens  
**Lana Kandalaft**, *Ludwig Institute for Cancer Research, Lausanne Branch (LICR) / CHUV / UNIL, CH*
- 16:30 - 17:00** Overcoming innate-immune resistance in cancer  
**Nina Bhardwaj**, *The Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, US*
- 17:00 - 17:15** *Selected talk:* PD-L1 checkpoint blockade promotes regulatory T-cell activity which underlies therapy resistance  
**Mandy van Gulijk**, *Erasmus Medical Center Rotterdam, NL; Erasmus MC Cancer Institute, NL*
- 17:15 - 17:45** Microbiota in cancer progression and metastases  
**Maria Rescigno**, *Humanitas University, IT*
- 17:45 - 18:45** Meet the speaker / editor session and reception
- 18:45 - 19:45** Guided walk through Leuven
- 20:00 - 22:30** Conference dinner at Faculty Club

08:30 - 09:00 Welcome coffee

## Session 4

### T CELL/ IMMUNOTHERAPY

Chair: Karin de Visser

- 09:00 - 09:30** T-cell dynamics in melanoma patients receiving TIL therapy and generation of enriched cell products  
**Alexandre Harari**, *Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne, CH*
- 09:30 - 10:00** Tissue-resident gamma delta T cell function during tumor initiation, metastasis and immunotherapy treatment  
**Seth Coffelt**, *Institute of Cancer Sciences, University of Glasgow and Cancer Research UK Beatson Institute, UK*
- 10:00 - 10:30** Regulatory T cells as determinants of adaptive and innate immune function in brain tumours  
**Sergio A. Quezada**, *University College London Cancer institute, UK*
- 10:30 - 10:45** *Selected talk:* The role of tumor-specific CD4 T cells in CD8 T cell-mediated anti-tumor immunity  
**Gabriel Espinosa-Carrasco**, *Memorial Sloan Kettering Cancer Center, US*
- 10:45 - 11:15** Coffee break

## Session 5

### PRECISION IMMUNO-ONCOLOGY

Chair: Pierre van der Bruggen

- 11:15 - 11:45** Dissecting and modulating reactive anti-tumor immunity in human cancers  
**Daniele Thommen**, *The Netherlands Cancer Institute, NL*
- 11:45 - 12:15** Towards deciphering the highly heterogeneous peptidomic landscape in melanoma  
**Yardena Samuels**, *Department of Molecular Cell Biology, Weizmann Institute of Science, IL*
- 12:15 - 12:45** Informing precision immuno-oncology  
**Zlatko Trajanoski**, *Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, AT*
- 12:45 - 13:00** *Selected talk:* Better biomarker for response to immune checkpoint inhibition therapy: Analysis of neoepitope immunogenicity by neoIM  
**Lena Pfitzer**, *myNEO, BE*
- 13:00 - 13:05** *Company pitch:* Multi-Omic Tools for Therapeutic Discovery, Translational Research and Accelerating Clinical Outcomes  
**Harry Veerman**, *Benelux Senior Sales Manager, Fluidigm, NL*
- 13:05 - 13:45** Lunch
- 13:45 - 14:45** Poster session 2 | numbers 45 - 87

## IMMUNE ESCAPE

---

Chairs: Gabriele Bergers

- 14:45 - 15:15** CD8 T cells at the intersection of cancer and autoimmunity  
**Andrea Schietinger**, *Memorial Sloan Kettering Cancer Center, Immunology Program, US*
- 15:15 - 15:45** Downregulation of the T cell activating receptor CD226 drives resistance to cancer immunotherapy  
**Tobias Bald**, *Institute of Experimental Oncology, University Hospital Bonn, DE*
- 15:45 - 16:15** Coffee break
- 16:15 - 16:45** Regulation of myeloid-derived suppressor cells in cancer  
**Dmitry Gabrilovich**, *ICC, Early Oncology R&D, AstraZeneca, US*
- 16:45 - 17:15** Nanobody-mediated modulation of immunosuppressive cells in the tumor microenvironment  
**Jo Van Ginderachter**, *VIB-UGent Center for Inflammation Research, BE*
- 17:15 - 17:30** Closing remarks and poster prizes ceremony